Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.

The researchers found that the 5-year risks for revision among 3691 participants was 5.6% for patients in the weight gain or stable weight group compared with 3.9% in patient with greater than 10% ...